Abeona Therapeutics (NASDAQ: ABEO) and PRA Health Sciences (NASDAQ:PRAH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Volatility & Risk
Abeona Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, PRA Health Sciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
This table compares Abeona Therapeutics and PRA Health Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PRA Health Sciences||3.85%||22.77%||7.04%|
Institutional & Insider Ownership
62.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 99.3% of PRA Health Sciences shares are held by institutional investors. 6.8% of Abeona Therapeutics shares are held by company insiders. Comparatively, 2.1% of PRA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Abeona Therapeutics and PRA Health Sciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PRA Health Sciences||0||1||10||0||2.91|
Abeona Therapeutics presently has a consensus target price of $28.25, suggesting a potential upside of 78.80%. PRA Health Sciences has a consensus target price of $95.18, suggesting a potential upside of 2.50%. Given Abeona Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Abeona Therapeutics is more favorable than PRA Health Sciences.
Earnings and Valuation
This table compares Abeona Therapeutics and PRA Health Sciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Abeona Therapeutics||$890,000.00||830.48||-$21.87 million||($0.66)||-23.94|
|PRA Health Sciences||$2.26 billion||2.62||$86.92 million||$1.52||61.09|
PRA Health Sciences has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks.
PRA Health Sciences beats Abeona Therapeutics on 8 of the 13 factors compared between the two stocks.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
About PRA Health Sciences
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company’s service offerings include product registration, strategic solutions and early development services.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.